Fluidigm Corp
F:FLB
Operating Margin
Fluidigm Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
F
|
Fluidigm Corp
F:FLB
|
401.8m EUR |
-74%
|
|
US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
15%
|
|
US |
![]() |
Thermo Fisher Scientific Inc
NYSE:TMO
|
161.4B USD |
18%
|
|
US |
![]() |
Danaher Corp
NYSE:DHR
|
135.9B USD |
22%
|
|
KR |
![]() |
Samsung Biologics Co Ltd
KRX:207940
|
75.7T KRW |
32%
|
|
CH |
![]() |
Lonza Group AG
SIX:LONN
|
38.8B CHF |
18%
|
|
CN |
![]() |
WuXi AppTec Co Ltd
SSE:603259
|
239.1B CNY |
27%
|
|
US |
![]() |
Agilent Technologies Inc
NYSE:A
|
33B USD |
23%
|
|
US |
![]() |
IQVIA Holdings Inc
NYSE:IQV
|
32.6B USD |
15%
|
|
US |
![]() |
Mettler-Toledo International Inc
NYSE:MTD
|
25.3B USD |
29%
|
|
IN |
![]() |
Divi's Laboratories Ltd
NSE:DIVISLAB
|
1.8T INR |
28%
|
Fluidigm Corp
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Fluidigm Corp's most recent financial statements, the company has Operating Margin of -74.4%.